

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0461US1	Application No. 10/542,326
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Alan Wellington Faull et al.	
		Filing Date July 13, 2005	Group Art Unit 1626
(37 CFR §1.98(b))			

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,258,357	11/02/1993	Muenster et al.			
	AB	5,571,810	11/05/1996	Matsuo et al.			
	AC	5,679,670	10/21/1997	Dean et al.			
	AD	6,048,880	04/11/2000	Kawai et al.			
	AE	6,380,214	04/30/2002	Gant et al.			
	AF	6,414,013	07/02/2002	Fancelli et al.			
	AG	6,699,854	03/02/2004	Wang et al.			
	AH	6,809,088	10/26/2004	Chabrier de Lassauniere et al.			
	AI	6,835,745	12/28/2004	Coghlan et al.			
	AJ	6,875,790	04/05/2005	Bertenshaw et al.			
	AK	6,881,735	04/19/2005	Schindler et al.			
	AL	6,881,741	04/19/2005	Chan Chun Kong et al.			
	AM	7,019,027	03/28/2006	Linden et al.			
	AN	7,084,170	08/01/2006	Grossman et al.			
	AO	7,084,171	08/01/2006	Grainger et al.			
	AP	7,098,240	08/29/2006	Griffiths et al.			
	AQ	7,125,896	10/24/2006	Faull et al.			
	AR	7,166,639	01/23/2007	Wan et al.			
	AS	7,196,106	03/27/2007	Duffy et al.			
	AT	US-2006-0111431	05/25/2006	Morley et al.			
	AU	US-2006-0058522	03/16/2006	Faull et al.			
	AV	US-2007-0015819	01/18/2007	Faull et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AW	EP 0202538	11/26/1986	EP			English Abstract attached	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0461US1	Application No. 10/542,326
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Alan Wellington Faull et al.	
		Filing Date July 13, 2005	Group Art Unit 1626
(37 CFR §1.98(b))			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AX	EP 0853083	07/15/1998	EP				
	AY	EP 0908456	04/14/1999	EP			English Abstract attached	
	AZ	GB 1468012	03/23/1977	United Kingdom				
	AAA	GB 2195634	04/13/1988	United Kingdom				
	ABB	WO 98/02430	01/22/1998	WIPO				
	ACC	WO 98/54116	12/03/1998	WIPO				
	ADD	WO 99/46244	09/16/1999	WIPO				
	AEE	WO 00/71532	11/30/2000	WIPO				
	AFF	WO 01/58890	08/16/2001	WIPO				
	AGG	WO 01/98290	12/27/2001	WIPO				
	AHH	WO 02/30353	04/18/2002	WIPO				
	ALL	WO 02/46171	06/13/2002	WIPO				
	AJJ	WO 03/010158	02/06/2003	WIPO				
	AKK	WO 03/010163	02/06/2003	WIPO				
	ALL	WO 03/029241	04/10/2003	WIPO				
	AMM	WO 03/028731	04/10/2003	WIPO				
	ANN	WO 2004/063185	07/29/2004	WIPO				
	AOO	WO 2004/063186	07/29/2004	WIPO				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	APP	Awada et al., "The pipeline of new anticancer agents for breast cancer treatment in 2003", <i>Critical Reviews in Oncology/Hematology</i> 48:45-63 (2003)
	AQQ	Berkow et al., <i>The Merck Manual of Diagnosis and Therapy</i> , 16 <sup>th</sup> Edition, © 1992, Merck Research Laboratories, Rahway, NJ, pages 1488 and 2664
	ARR	Chen et al., "TNF-R1 Signaling: A Beautiful Pathway", <i>Science</i> 296:1634-1635 (2002)
	ASS	Compston et al., "Multiple sclerosis", <i>The Lancet</i> 359:1221-1231 (2002)
	ATT	Du et al., "Aryl ureas represent a new class of anti-trypanosomal agents", <i>Chemistry &amp; Biology</i> 7:733-742 (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>06275-0461US1</b>	Application No. <b>10/542,326</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Alan Wellington Faull et al.</b>	
		Filing Date <b>July 13, 2005</b>	Group Art Unit <b>1626</b>
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AUU	Golub et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", <i>Science</i> 286:531-537 (1999)
	AVV	Gripenberg, "Common serological features in rheumatoid arthritis and yersinia arthritis", <i>Scand. J. Rheumatology</i> 10:85-91 (1981)
	AWW	Hartung et al., "What do we know about the mechanism of action of disease-modifying treatments in MS?" <i>J Neurol</i> 251(Suppl. 5):V/12-V/29 (2004)
	AXX	Lala et al., "Role of nitric oxide in tumor progression: Lessons from experimental tumors", <i>Cancer and Metastasis Reviews</i> 17:91-106 (1998)
	AYY	Parrish et al., "Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders", <i>CAPLUS</i> 138:304153, 2003
	AZZ	Zayed et al., "Studies on 5-aminopyrazole derivatives. Synthesis of some new fused pyrazole derivatives", <i>Monatsh. Chem.</i> 115:431-436 (1984)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	